We use cookies to make this site as useful as possible. Read our cookie policy or ignore.

Intellectual property: A shift in moral goalposts

13 March 2015

Intellectual property: A shift in moral goalposts

Rules around patenting research from human stem cells has changed with scientific advancements

A recent decision by the Court of Justice of the European Union (CJEU) concerning International Stem Cell Corporations (ISCC) patent applications caught my eye. It raises an interesting dilemma about the patenting, in the EU, of human embryonic stem cells (hESCs), and whether the biotech industry’s approach in using hESCs (particularly in the US) as opposed to induced pluripotent stem cells (iPSCs) – which are generated from adult cells –  poses any risks when it comes to patenting.


Please sign in to read more

Forgotten your password?

Do you need access?

Some Governance + Compliance articles are only available to subscribers

Don’t fall behind. Choose your route.

Become an Affiliate member

Subscribe to Governance + Compliance magazine